Corrigendum


M. Bhalla*, Z. El-Housseini, R. Asaria

Royal Free Foundation Trust Hospital

The authors regret to inform that the blindness by embolisation was caused by activated mesenchymal pericyte plasma injections, which is also known as Lipgems® rather than ‘Platelet-rich plasma’ injection. In the original publication, the authors found only one previous ‘Platelet-rich plasma’ injection associated blindness however, in the case of Lipgems® there was no evidence whatsoever in the literature. Despite the change in the type of the treatment the patient received, the case report maintains its rarity and learning point of disclosing visual loss as a rare complication of any temporomandibular injection.

The authors would like to remove:

‘Platelet-rich plasma (PRP) is an autologous product composed of growth factors that can be up to 8 times the level in normal blood. Studies have shown it to be more clinically and radiologically efficacious when compared to other forms of intraarticular injections like steroids and Hyaluronic acid (HA)’.

The authors would like to add:

‘Mesenchymal pericyte plasma injections can be harvested from subcutaneous fat tissues, and this source often gives patients the opportunity to have 500 times more stem cells than bone marrow extracted stem cells. Activated mesenchymal pericyte plasma injections have already been used for osteoarthritis where significant therapeutic evidence has been well documented in the literature.’

The authors would like to apologise for any inconvenience caused.

References


https://doi.org/10.1016/j.bjoms.2022.03.008

* Corresponding author.
E-mail address: m.bhalla@nhs.net (M. Bhalla).